Aktaa Suleman, Gale Chris P, Brida Margarita, Giannakoulas George, Kovacs Gabor, Adir Yochai, Benza Raymond L, Böhm Michael, Coats Andrew, D'Alto Michele, Escribano-Subias Pilar, Ferrari Pisana, Galiè Nazzareno, Gibbs J Simon R, Gin-Sing Wendy, Hoeper Marius M, Humbert Marc, Lang Irene M, Maron Bradley A, Meszaros Gergely, Vonk Noordegraaf Anton, Price Laura C, Pepke-Zaba Joanna, Rådegran Göran, Reis Abilio, Sitbon Olivier, Torbicki Adam, Ulrich Silvia, Rosenkranz Stephan, Delcroix Marion
Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Leeds Institute for Data Analytics and Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Eur J Heart Fail. 2023 Apr;25(4):469-477. doi: 10.1002/ejhf.2830. Epub 2023 Apr 4.
To develop a suite of quality indicators (QIs) for the evaluation of the care and outcomes for adults with pulmonary arterial hypertension (PAH).
We followed the European Society of Cardiology (ESC) methodology for the development of QIs. This included (i) the identification of key domains of care for the management of PAH, (ii) the proposal of candidate QIs following systematic review of the literature, and (iii) the selection of a set of QIs using a modified Delphi method. The process was undertaken in parallel with the writing of the 2022 ESC/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension and involved the Task Force chairs, experts in PAH, Heart Failure Association (HFA) members and patient representatives. We identified five domains of care for patients with PAH: structural framework, diagnosis and risk stratification, initial treatment, follow-up, and outcomes. In total, 23 main and one secondary QIs for PAH were selected.
This document presents the ESC QIs for PAH, describes their development process and offers scientific rationale for their selection. The indicators may be used to quantify and improve adherence to guideline-recommended clinical practice and improve patient outcomes.
制定一套质量指标（QIs），用于评估成人肺动脉高压（PAH）患者的治疗及预后。
我们遵循欧洲心脏病学会（ESC）制定质量指标的方法。这包括：（i）确定PAH管理的关键治疗领域；（ii）在对文献进行系统综述后提出候选质量指标；（iii）使用改良的德尔菲法选择一组质量指标。该过程与2022年ESC/欧洲呼吸学会（ERS）肺动脉高压诊断和治疗指南的编写同时进行，参与人员包括工作组主席、PAH专家、心力衰竭协会（HFA）成员和患者代表。我们确定了PAH患者的五个治疗领域：结构框架、诊断和风险分层、初始治疗、随访及预后。总共选择了23个PAH主要质量指标和1个次要质量指标。
本文介绍了ESC制定的PAH质量指标，描述了其制定过程，并为指标的选择提供了科学依据。这些指标可用于量化和提高对指南推荐临床实践的依从性，并改善患者预后。
